In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Published Sep 22, 2020

In Certain Types of Lung Cancer, Targeted Drug Tagrisso Slashed Recurrence Rates, New Study Says

Already approved for EGFR-positive metastatic non-small cell lung cancer, osimertinib (Tagrisso ) brings major benefits in early cancer, too.

NOW
PLAYING
New Treatment Shows Huge Promise For Decreasing COVID Symptom-- Are Monoclonal Antibodies An Option for Cancer Patients?
NOW
PLAYING
A Former Paramedic, 48, Is Tragically Diagnosed with Advanced Lung Cancer After an 8-Month Delay to See His Doctor Because of COVID-19
NOW
PLAYING
Beth Chapman's Kids Reunite for First Time Since She Lost Cancer Battle & It's Everything
NOW
PLAYING
Radiation Therapy in Just One Day
NOW
PLAYING
Tremendous Concern Inside Cancer Centers; A Top Doctor Says She's Very Worried About the Rise in COVID Cases in the Next Few Weeks
NOW
PLAYING
It's Been 19 Years Since The Beatles' George Harrison Passed From Throat & Lung Cancer; Some of the Incredible Medical Advances We've Seen Since

SurvivorNetTV.
Hope. Science.
Inspiration.

Discover SNTV
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.